Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Spexin

NPQ Peptide · Appetite Suppressor

Evidence grade 1 of 5, Untested. Read how the Atlas grades evidence.

Spexin is a 14-amino-acid neuropeptide (galanin/kisspeptin family, ligand at GALR2/GALR3) whose plasma and adipose levels are consistently reduced in human obesity and type 2 diabetes across observational cohorts, including obese children (Kolodziejski/Gawel; Kumar; systematic review by Behrooz 2021). Every intervention finding, reduced food intake and weight loss after spexin administration, comes from animal models (diet-induced obese mice and rats, goldfish) or in-vitro adipocyte work, and there are no human trials of spexin administration and no ClinicalTrials.gov registration. Because human evidence is association-only and all mechanistic dosing data are animal or in-vitro, ev remains 1.

FDA
No FDA status; unapproved research chemical with no drug application and no ClinicalTrials.gov registration for administered spexin
WADA
Not prohibited

Reference only. Not medical advice.

What can go wrong

Unapproved research chemical with zero human intervention data; sold not for human consumption, safety in people is uncharacterized.

Talk to a clinician before taking this. The Atlas can tell you what has been studied about Spexin. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.

A neuropeptide that suppresses food intake and promotes fat utilization; plasma levels correlate inversely with obesity. A potential weight-management target, still very early.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Weight management (research)
  • Appetite regulation

How it is supposed to work

Spexin is a small neuropeptide related to the galanin family that acts through galanin receptors and suppresses appetite (it reduces food intake, partly via melanocortin and opioid pathways). Its levels fall in obesity, which has made it a candidate signal in metabolic and weight research, alongside roles in reproduction, cardiovascular function and pain.

Spexin, also called neuropeptide Q, is a 14-amino-acid peptide discovered through bioinformatics and belonging to the same family as galanin and kisspeptin. It works through two of the galanin receptors and is found throughout the brain and metabolic tissues like fat and pancreas.

Type
Neuropeptide
Length
14 amino acids
Receptors
Galanin 2 and 3
Human data
Correlational
Therapeutic trials
None
Status
Research

Low In Obesity, Slimming In Rodents, Untested In People

Spexin has one of the more grounded stories among the early-stage metabolic peptides, but it is still a target rather than a therapy. The grounding is real human data: spexin is the single most down-regulated gene in the fat of obese people, and circulating levels are low in obesity and type 2 diabetes, tracking with blood sugar and lipids. In animals, giving spexin causes weight loss by suppressing appetite, reducing fat uptake and improving insulin sensitivity, which is exactly what an anti-obesity signal should do. The honest limits are equally clear. The human evidence is correlational, the weight-loss effects come from rodents, and there are no human therapeutic trials, no approval and no established dosing. In an era when the GLP-1 and incretin drugs actually produce large, proven weight loss in people, spexin is an unproven alternative pathway, of real scientific interest but sold gray-market well ahead of any human results.

Safety in detail

Human evidence for spexin is limited to observational associations between naturally circulating levels and obesity or diabetes. No trial has administered spexin to people, so its safety, dosing, and effects when injected are unknown, and material sold online is unregulated.

  • Spexin is an endogenous research peptide with no established administered-form human safety data.
  • Its therapeutic potential in weight control is unproven.
  • It is not a consumer product; any such material would be gray-market and unverified.
  • Not approved for any use.

Children and teenagers

Spexin has no validated pediatric use and is an unapproved research peptide; pediatric obesity is managed through established care, not gray-market peptides.

What people get wrong

Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

Spexin reaches users through the gray-market research-peptide trade, sold for weight loss and metabolic health on its correlational human data and rodent efficacy. Its more serious commercial future lies in pharmaceutical galanin-receptor agonists for obesity and diabetes, not in the native peptide.

How we got here

Spexin was first identified in 2007 by Mirabeau and colleagues, who used a hidden Markov model bioinformatics screen of the human proteome to flag a conserved 14-amino-acid peptide, and it was independently characterized around the same period under the name Neuropeptide Q (NPQ). The mature peptide is encoded by the C12orf39 gene and is highly conserved from fish to mammals. Sonmez and later Kim and colleagues (2009-2016) defined its receptors as the galanin receptors GALR2 and GALR3, placing it in the galanin/kisspeptin family thought to have co-evolved with galanin through vertebrate whole-genome duplication. It has never been developed into a named human drug product; interest is as an endogenous obesity and diabetes marker and as a scaffold for GALR2-selective agonist research, and any material offered for sale circulates as an unbranded research chemical.

Spexin was discovered around 2007 through bioinformatic screening and assigned to the galanin and kisspeptin family. Human studies later found it markedly depleted in obesity and diabetes, and rodent studies showed it causes weight loss, establishing it as a metabolic drug target still awaiting human therapeutic evidence.

The numbers behind the grade

Type
Neuropeptide (galanin-related)
Action
Appetite suppression
In obesity
Reduced
Stage
Preclinical
Approved
No
Use
Research

The people taking it

An emerging appetite-related neuropeptide of interest in obesity research, studied as a marker and potential target, but not a consumer compound.

Spexin’s users are weight-loss and metabolic-health seekers in the gray-market peptide community, plus the researchers pursuing its obesity and diabetes potential.

Studied in research for appetite and metabolic regulation and as an obesity marker; it has no approved consumer use.

Set against the alternatives

Spexin belongs to the galanin and kisspeptin family and is, among the neuropeptides here, one of the better grounded thanks to real human marker data. Against the proven obesity drugs covered in this library, like the GLP-1 and incretin agents, it is an earlier, unproven pathway rather than a treatment. Against Phoenixin it shares the early-stage, multifunctional character but with stronger metabolic human correlations.

What we do not know

  • Whether restoring spexin can aid weight control in humans.
  • How its appetite-suppressing pathway could be targeted by a drug.
  • What its roles beyond metabolism amount to.

The market for this

What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.

There is no approved consumer route. It exists mainly as a research compound; given the limited human data, self-experimentation is not advisable.

Not produced as an approved drug for this use; any consumer-facing material is research-use-only, typically synthesized overseas in China, with no quality assurance and frequently no certificate of analysis.

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Spexin.

  • Timeline. We have not built the dated record of research and regulatory events.
  • Supply chain. We have not mapped where it is made.
  • What could change. No forward-looking summary yet.

Sources

The studies that matter

  • Appetite and obesity studies2010s

    Spexin reduces food intake in animal models and is found at lower levels in people with obesity, suggesting a role in weight regulation.

  • Mechanism2010s-2020s

    Its hypophagic effect involves galanin receptors and downstream anorexigenic pathways such as POMC.

  • Marker research2010s-2020s

    Spexin has been studied as a marker in obesity, metabolic and eating-related conditions.